J Invest Dermatol: Dupilumab's blocking effect on IL-4R alpha reduces the implantation of glucosin bacteria on the skin of patients with admissopathy and increases the diversity of microorganisms.

Dupilumab is an all-human antibody of leukocyte interferon-4 receptonic alpha that improves symptoms and signs of moderate to severe atopic dermatitis (AD).
a double-blind, placebo-controlled study aimed at determining the effects of Dupiru monoantigen on staphylococcus aura and microbiobidity on the skin was published online at J Invest Dermatol. The
study included 54 patients with moderate to severe AD, randomly grouped (1:1), treated with dupiluma (200mg per week) or a placebo for 16 weeks, and analyzed bacterial DNA from swabs collected from lesions and non-pathogenic skin.
the relative abundance of microbiobiivity and staphylococcus through DNA sequencing of 16S RNA, and the absolute abundance of Staphylococcus ale through quantitative PCR.
results showed that the microbiobiguity of the diseased skin was lower before treatment, and the overall abundance of Staphylococcus alucus was higher than that of non-pathogenic skin.
treatment of Duptilumab, microbiobiguity increased and Staphylococcus amethyst decreased.
and lesions of the skin have significant changes.
reduction in Staphylococcus amethyst abundance during Dupilumab treatment was associated with clinical improvement of AD and biomarkers of type 2 immunity.
to sum up, the results of the study show that the clinical improvement of AD mediated by leukocytocular meso-4 receptosis alpha inhibition and subsequent type 2 inflammation inhibition were associated with increased microbiobiivity and reduced Staphylococcus aureus abundance.
.